S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Arch Therapeutics Stock Forecast, Price & News

-0.01 (-5.99 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $0.16
50-Day Range
MA: $0.16
52-Week Range
Now: $0.16
Volume238,322 shs
Average Volume485,262 shs
Market Capitalization$30.31 million
P/E RatioN/A
Dividend YieldN/A
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.
Arch Therapeutics logo


Overall MarketRank

1.16 out of 5 stars

Medical Sector

760th out of 1,558 stocks

Surgical & Medical Instruments Industry

79th out of 137 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolOTCMKTS:ARTH
Previous SymbolNASDAQ:ARTH



Sales & Book Value

Annual SalesN/A
Book Value($0.01) per share


Net Income$-4,690,000.00


Market Cap$30.31 million
Next Earnings Date2/4/2021 (Estimated)
OptionableNot Optionable
-0.01 (-5.99 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ARTH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions

How has Arch Therapeutics' stock price been impacted by COVID-19?

Arch Therapeutics' stock was trading at $0.2050 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARTH stock has decreased by 23.4% and is now trading at $0.1570.
View which stocks have been most impacted by COVID-19

Is Arch Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arch Therapeutics stock.
View analyst ratings for Arch Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Arch Therapeutics?

Wall Street analysts have given Arch Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arch Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Arch Therapeutics' next earnings date?

Arch Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Arch Therapeutics

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) released its quarterly earnings results on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.01.
View Arch Therapeutics' earnings history

What price target have analysts set for ARTH?

2 equities research analysts have issued 1 year target prices for Arch Therapeutics' stock. Their forecasts range from $1.25 to $1.50. On average, they expect Arch Therapeutics' share price to reach $1.38 in the next twelve months. This suggests a possible upside of 775.8% from the stock's current price.
View analysts' price targets for Arch Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Arch Therapeutics' key competitors?

What other stocks do shareholders of Arch Therapeutics own?

Who are Arch Therapeutics' key executives?

Arch Therapeutics' management team includes the following people:
  • Dr. Terrence W. Norchi, Co-Founder, Chairman, Pres, CEO & Sec. (Age 55, Pay $519.2k)
  • Mr. Richard E. Davis, CFO & Treasurer (Age 62, Pay $387.26k)
  • Dr. Rutledge Ellis-Behnke Ph.D., Co-Founder & Scientific Advisor
  • Dr. Steven A. Kates, VP of Technology
  • Dr. Elaine Whitmore, Regulatory Consultant & Advisor
  • Dr. Avtar S. Dhillon, Bus. Advisor (Age 59)
  • Mr. Daniel C. Wadsworth Jr., Advisor & Consultant of Wound Care Commercialization (Age 66)
  • Dr. Dmitry Nepomnayshy, Clinical Advisor

What is Arch Therapeutics' stock symbol?

Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."

How do I buy shares of Arch Therapeutics?

Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arch Therapeutics' stock price today?

One share of ARTH stock can currently be purchased for approximately $0.16.

How big of a company is Arch Therapeutics?

Arch Therapeutics has a market capitalization of $30.31 million. Arch Therapeutics employs 7 workers across the globe.

What is Arch Therapeutics' official website?

The official website for Arch Therapeutics is www.archtherapeutics.com.

How can I contact Arch Therapeutics?

Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.